164 related articles for article (PubMed ID: 34878221)
1. How the rise of testosterone therapy in men was inspired by lizard research with David Crews.
Morgentaler A
J Exp Zool A Ecol Integr Physiol; 2022 Jan; 337(1):103-106. PubMed ID: 34878221
[TBL] [Abstract][Full Text] [Related]
2. Safety of testosterone therapy in men with prostate cancer.
Morgentaler A; Caliber M
Expert Opin Drug Saf; 2019 Nov; 18(11):1065-1076. PubMed ID: 31495240
[No Abstract] [Full Text] [Related]
3. Is testosterone a friend or a foe of the prostate?
Jannini EA; Gravina GL; Morgentaler A; Morales A; Incrocci L; Hellstrom WJ
J Sex Med; 2011 Apr; 8(4):946-55. PubMed ID: 21457469
[TBL] [Abstract][Full Text] [Related]
4. Testosterone therapy in prostate cancer: is it still a controversy?
Bart AS; Van Hoof A; Badre-Hume R; Selvarajah J; Robillard K; Albala DM
Curr Opin Urol; 2022 Nov; 32(6):598-606. PubMed ID: 36081393
[TBL] [Abstract][Full Text] [Related]
5. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.
Morgentaler A; Traish AM
Eur Urol; 2009 Feb; 55(2):310-20. PubMed ID: 18838208
[TBL] [Abstract][Full Text] [Related]
6. A new era of testosterone and prostate cancer: from physiology to clinical implications.
Khera M; Crawford D; Morales A; Salonia A; Morgentaler A
Eur Urol; 2014 Jan; 65(1):115-23. PubMed ID: 24011426
[TBL] [Abstract][Full Text] [Related]
7. Risk of Testosterone Flare in the Era of the Saturation Model: One More Historical Myth.
Krakowsky Y; Morgentaler A
Eur Urol Focus; 2019 Jan; 5(1):81-89. PubMed ID: 28753828
[TBL] [Abstract][Full Text] [Related]
8. Testosterone Therapy After Prostate Cancer Treatment: A Review of Literature.
Natale C; Carlos C; Hong J; Khera M; Baum N; Raheem OA
Sex Med Rev; 2021 Jul; 9(3):393-405. PubMed ID: 33516741
[TBL] [Abstract][Full Text] [Related]
9. Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry.
Morales A
BJU Int; 2011 May; 107(9):1369-73. PubMed ID: 21518230
[TBL] [Abstract][Full Text] [Related]
10. Testosterone Therapy in Advanced Prostate Cancer.
Chedrawe E; Sathe A; White J; Ory J; Ramasamy R
Androg Clin Res Ther; 2022; 3(1):180-186. PubMed ID: 36684061
[TBL] [Abstract][Full Text] [Related]
11. Testosterone and prostate cancer: revisiting old paradigms.
Isbarn H; Pinthus JH; Marks LS; Montorsi F; Morales A; Morgentaler A; Schulman C
Eur Urol; 2009 Jul; 56(1):48-56. PubMed ID: 19375844
[TBL] [Abstract][Full Text] [Related]
12. The role of testosterone replacement therapy and statin use, and their combination, in prostate cancer.
Lopez DS; Huang D; Tsilidis KK; Canfield S; Khera M; Baillargeon JG; Kuo YF; Peek MK; Platz EA; Markides K
Cancer Causes Control; 2021 Sep; 32(9):965-976. PubMed ID: 34041642
[TBL] [Abstract][Full Text] [Related]
13. Association of the extent of therapy with prostate cancer in those receiving testosterone therapy in a US commercial insurance claims database.
Lopez DS; Huang D; Tsilidis KK; Khera M; Williams SB; Urban RJ; Panagiotou OA; Kuo YF; Baillargeon J; Farias A; Krause T
Clin Endocrinol (Oxf); 2019 Dec; 91(6):885-891. PubMed ID: 31498469
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and Treatment of Testosterone Deficiency: Updated Recommendations From the Lisbon 2018 International Consultation for Sexual Medicine.
Morgentaler A; Traish A; Hackett G; Jones TH; Ramasamy R
Sex Med Rev; 2019 Oct; 7(4):636-649. PubMed ID: 31351915
[TBL] [Abstract][Full Text] [Related]
15. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of androgen deprivation therapy in prostate cancer patients.
Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
[TBL] [Abstract][Full Text] [Related]
17. Endogenous and exogenous testosterone and prostate cancer: decreased-, increased- or null-risk?
Lopez DS; Advani S; Tsilidis KK; Wang R; Canfield S
Transl Androl Urol; 2017 Jun; 6(3):566-579. PubMed ID: 28725600
[TBL] [Abstract][Full Text] [Related]
18. Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer.
Gagliano-Jucá T; Travison TG; Nguyen PL; Kantoff PW; Taplin ME; Kibel AS; Manley R; Hally K; Bearup R; Beleva YM; Huang G; Edwards RR; Basaria S
J Pain Symptom Manage; 2018 Feb; 55(2):307-317.e1. PubMed ID: 28941963
[TBL] [Abstract][Full Text] [Related]
19. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.
Muller RL; Gerber L; Moreira DM; Andriole G; Castro-Santamaria R; Freedland SJ
Eur Urol; 2012 Nov; 62(5):757-64. PubMed ID: 22658758
[TBL] [Abstract][Full Text] [Related]
20. Controversies in Testosterone Therapy.
Twitchell DK; Pastuszak AW; Khera M
Sex Med Rev; 2021 Jan; 9(1):149-159. PubMed ID: 33309270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
